3 automated stage on an epifluorescence microscope (Nikon Eclipse TE200, Melville, NY, USA). We processed 191 the acquired images and videos using Nikon Elements software. 192 193 Data Analysis: 194 We quantified the numbers of rolling, adherent, and migrating leukocytes in the bMFA using Nikon Elements 195 software. We considered any leukocyte traveling at a velocity below the critical velocity as a rolling cell. We 196 estimated critical velocity from a cell velocity flowing in the centerline (v cc ) as v crit = v cc × ε × (2 − ε), where ε 197 is the cell-to-vessel diameter ratio. We considered any cell that did not move for 30 seconds as adherent. 198 199 Statistics. 200 For analysis of the microarray data, we normalized expression patterns using quantile normalization in R 201 statistical software and deemed differences as significant if there were > 2-fold change between groups if the p-202 value (adjusted for multiple comparisons using the Benjamini-Hochberg procedure) was below 0.05.
204
For analysis of human tissue RNAseq data, due to the skewness and heteroscedasity of the raw counts data, we 205 performed the Mann-Whitney test to compare Esm-1, CD31, and Cadherin 5 expression levels in kidney with 206 the other five highest Esm-1-expressing tissues (lung, thyroid, aorta, adrenal gland, and tibial artery). We 207 deemed differences to be statistically significant if the p-value (adjusted for multiple comparisons using a 208 Bonferroni correction) was below 0.05.
210
For all other experiments, we used Student's t-test to compare two experimental groups, and one-or two-way 211 analysis of variance to compare three or more experimental groups. We expressed the results as mean +/-212 standard error of the mean and deemed differences to be statistically significant if the p-value was below 0.05. By microarray analysis of total glomerular RNA, we aligned gene transcripts for each sample by the mean 228 expression in each group in reference to non-diabetic DN-resistant mice. We then focused on gene transcripts in 229 which the mean fold change was greater or less than 2-fold different between diabetic DN-susceptible and DN-230 resistant mice. This filter narrowed the list from approximately 25,000 to 250 genes. The heat map for this 231 comparison is depicted in Fig 1. To further refine the analysis, we included only genes that were significantly 232 different between diabetic, but not non-diabetic, groups. We identified 22 significantly higher-expressed genes 233 and eight lower-expressed genes between diabetic DN-susceptible and DN-resistant mice ( Table 1) . Pathway 234 analysis of this set of genes identified the regulation of the immune system as a significant feature of this 235 comparison. Of the processes identified, ranked by lowest p-value, four of the top five were related to 236 inflammation or the immune system ( Table 2 ). In addition to enrichment for immune-related genes, we noted 237 11 three differentially expressed genes that were not originally classified in the pathway analysis as regulators of 238 the immune system: Esm-1, Tsc22d3, and Midkine [23] [24] [25] . This enrichment analysis does not account for 239 directionality. We noted that among these three gene transcripts associated in the literature with inhibition of 240 leukocyte infiltration, expression of Esm-1 and Tsc22d3 [23, 24] were significantly lower in DN-susceptible 241 mice. In contrast, a gene transcript associated with promotion of leukocyte infiltration and more severe DN[25], 242 Midkine, was higher in DN-susceptible mice. We validated that these results were consistent between 243 microarray and qPCR experiments (Fig 2, Table S1 ), using distinct primer sites to target the mRNA sequence.
244
To begin to explore these differentially regulated genes with potential significance for DN, we selected Esm-1 245 for further characterization. High expression of Esm-1 and strain-specific difference is found in glomeruli. 300 To ascertain whether Esm-1 was ubiquitously or selectively expressed, we surveyed tissue-specific expression 301 in both humans and mice. We compared Esm-1 expression in datasets from several experiments involving 25 302 human tissues, and kidney Esm-1 mRNA is the highest, followed by lung (Fig 3A) . This difference was not 303 driven by differences in endothelial cell number as two markers for endothelial cells, CD31 and Cadherin 5[26], 304 are not similarly expressed across human tissues. We also compared Esm-1 expression in several tissues from 305 16 both DN-susceptible and DN-resistant mouse strains, and similar to humans, Esm-1 expression in kidney and 306 lung is highest (Fig 3B) . As in humans, this difference was not likely due to a difference in endothelial cell 307 number as CD31 and Cadherin 5 are not similarly expressed across tissues ( Fig 3C-D) [26]. Within kidney,
308
Esm-1 expression is significantly enriched for in glomeruli, and is only significantly lower in DN-susceptible 309 vs. resistant mice within this compartment (0.30 ± 0.09 vs. 2.81 ±1.12, p<0.05) (Fig 3E-G) . We next examined 310 the regulation of Esm-1 within glomeruli. Glomerular Esm-1 secretion inversely correlates with DN susceptibility. 333 Esm-1 is predominantly secreted[21] , and we were unable to detect Esm-1 in glomerular lysates by Western 334 blot analysis (data not shown). Therefore, to test whether Esm-1 protein expression in glomeruli is regulated by 335 diabetes, we isolated and cultured glomeruli, and assayed for Esm-1 in conditioned media by ELISA. Similar to 336 mRNA expression, four weeks after streptozotocin injection, glomeruli from DN-susceptible mice secreted 337 significantly less Esm-1 than DN-resistant mice (Fig 4A) . High glucose concentration increases glomerular-derived Esm-1. 353 To test whether glucose directly stimulates local glomerular Esm-1 secretion, we isolated glomeruli from non-354 diabetic DN-susceptible and DN-resistant mice, and assayed for Esm-1 mRNA and protein secretion in low or 355 high glucose media. Incubation in high glucose media increased Esm-1 mRNA and protein secretion in 356 glomeruli from both strains of mice (Fig 4B-C) , however the increase was significantly less in DN-susceptible 357 mice.
359
Systemic Esm-1 is dynamically regulated in diabetes. 360 The glomerulus is a major source of Esm-1 production (S3 Fig) , but the contribution of kidney production to 361 urine or serum Esm-1 has never been tested. We measured urine and serum Esm-1 from control and diabetic 362 mice after 4 weeks of vehicle or streptozotocin injection, respectively. Urine Esm-1 was significantly higher in 363 DN-resistant mice (Fig 5A) . To determine the contribution of circulating Esm-1, we measured serum Esm-1 in 364 similar groups of mice (Fig 5B) . In contrast to urine levels, diabetes significantly decreased circulating Esm-1.
365
To test the integrity of the glomerular filtration barrier, we measured the urine albumin-to-creatinine ratio, and 366 at 4 weeks after streptozotocin or vehicle injection, the ratio was similar among diabetic and non-diabetic mice 367 from both strains (Fig 5C) . Serum creatinine, a surrogate marker for glomerular filtration, was also similar 368 among all groups (Fig 5D) . Esm-1 inhibits leukocyte transmigration in a dose-dependent manner. 382 To test directly whether Esm-1 blocks leukocyte infiltration across an endothelial monolayer, we utilized 383 intravital microscopy and a biomimetic microfluidic assay (bMFA). Pre-treatment of leukocytes with 384 recombinant Esm-1 showed significantly decreased transmigration (Fig 6A) at 30 and 60 minutes in a dose-385 dependent manner, suggesting an inhibitory role of Esm-1 against leukocyte infiltration in DN. To investigate 386 the mechanism of decreased transmigration, we examined the role of recombinant Esm-1 to inhibit leukocyte 387 rolling and adhesion (Fig 6B-C) . In this ex vivo assay Esm-1 did not influence leukocyte adhesion. However, glomerular endothelial damage in DN in mice [17] . However, drugs that block leukocyte-endothelial interaction 421 in multiple tissues, e.g., efaluzimab [34] , have been removed from the market due to life-threatening infections, 422 highlighting the need for more tissue-specific targeting of the delicate interaction between leukocytes and 423 endothelial cells.
425
Esm-1 is highly expressed in kidney glomeruli. This relatively high kidney expression was not based on 426 endothelial number, and in fact, the relative difference between mouse kidney and lung could be accounted for 427 by higher levels of endothelial cell markers in lung. However, within mouse kidney, glomeruli had the highest 428 Esm-1 expression likely due to significant enrichment of endothelial cells in this compartment relative to the 429 tubulointerstitium. Interestingly, the strain-specific deficiency of glomerular Esm-1 in DN-susceptible mice was 430 not observed in other tissues. Therefore, we speculate that other glomerular-derived genes may influence Esm-1 431 transcription rather than a more systemic difference (e.g., Esm-1 promoter sequence) between these genetically Several pro-inflammatory mediators (e.g. TNFα) can induce expression of Esm-1[37], but heretofore, the 438 influence of the diabetic milieu on Esm-1 expression was unknown. Interestingly, this attenuated increase in a 439 susceptible cohort in a chronic disease is reminiscent of serum Esm-1 levels in patients with acute lung injury, 440 i.e., inflammatory mediators that accompany sepsis can induce Esm-1, but the patients with higher mortality, 441 presumably due to more inflammation, had a smaller increase in Esm-1 [38] . The relative deficiency of secreted 442 glomerular Esm-1 in DN-susceptible mice is congruent with the mRNA data but the magnitude of the difference 443 is attenuated. This could be due to alterations in glomerular endothelial cells due to isolation and plating of the 444 glomeruli. We found that after 24 hours, Esm-1 secretion decreased dramatically in culture (S3 Fig) . Perhaps 445 earlier time points would demonstrate a larger difference between strains of mice, but the detection limit of the 446 ELISA precluded this analysis. Differences in secretion between strains may also be influenced by differences 447 in trafficking of Esm-1 to the plasma membrane or degradation of secreted Esm-1.
449
To dissect the mechanisms that regulate Esm-1, we demonstrated that high glucose is sufficient to increase 450 glomerular Esm-1 mRNA and protein in vitro, and significantly more in DN-resistant compared to DN-451 susceptible mice. Cytokines that stimulate Esm-1 mRNA (e.g. VEGF) possibly mediate the effect of high 452 glucose as these cytokines are also acutely regulated by high glucose in cultured mesangial cells [39, 40] ; 453 however, whether these cytokines participate in DN susceptibility remains an area of further study. Esm-1 454 transcription is negatively regulated by the transcription factor hHex, but this gene was not differentially 455 expressed in our microarray analysis (data not shown) [41] . Future studies will explore the effects of high 456 glucose on hHex or its binding sites within the Esm-1 promoter and on mechanisms of differential transcription 457 (e.g. promoter methylation) and processing of Esm-1 in glomeruli.
459
To explore whether this differential expression of kidney Esm-1 is reflected in vivo, we measured urine and 460 serum Esm-1. In DN-resistant, compared to DN-susceptible mice, urine Esm-1 was significantly increased with 461 diabetes. Conversely, serum Esm-1 was surprisingly decreased with diabetes. Moreover, a marker of glomerular 462 membrane permeability, urine albumin-to-creatinine ratio, remained unchanged 4 weeks after induction of 463 diabetes. Thus, the filtered load of Esm-1 is not expected to increase. These results suggest that urine Esm-1
